An open-label, multicenter, phase Ib/II study of rebastinib in combination with paclitaxel in a dose-expansion cohort to assess safety and preliminary efficacy in patients with advanced or metastatic endometrial cancer.

Filip Janku,Erika Paige Hamilton,Christina Chu,Debra L. Richardson,Rebecca C. Arend,Keisuke Kuida,Haroun Achour,Rodrigo Ruiz-Soto,John L. Hays

An open-label, multicenter, phase Ib/II study of rebastinib in combination with paclitaxel in a dose-expansion cohort to assess safety and preliminary efficacy in patients with advanced or metastatic endometrial cancer.

2020

Filip Janku
Erika Paige Hamilton
Christina Chu
Debra L. Richardson
Rebecca C. Arend
Keisuke Kuida
Haroun Achour
Rodrigo Ruiz-Soto
John L. Hays

6085Background: Rebastinib is a switch control inhibitor targeting tunica interna endothelial cell kinase (TIE2). TIE2 is primarily expressed in endothelial cells playing a role in angiogenesis. TI...

Keywords:

Paclitaxel
Metastatic endometrial cancer
Oncology
open label
Internal medicine
Rebastinib
Medicine
Pathology
Cohort
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations